Karolina Wilczyńska

Dr. Karolina Wilczyńska

Department of Psychiatry, Bialystok Medical University

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MCMagdalena Choromańska
Magdalena Choromańska
AKAnna Klimiuk
Anna Klimiuk
PKPaula Kostecka-Sochoń
Paula Kostecka-Sochoń
Karolina WilczyńskaKarolina Wilczyńska
Karolina Wilczyńska
MKMikołaj Kwiatkowski
Mikołaj Kwiatkowski
Mateusz MaciejczykMateusz Maciejczyk
Mateusz Maciejczyk
Oxidative stress plays a crucial role in dementia pathogenesis; however, its impact on salivary secretion and salivary qualities is still unknown. This study included 80 patients with moderate dementia and 80 healthy age- and sex-matched individuals. Salivary flow, antioxidants (salivary peroxidase, catalase, superoxide dismutase, uric acid and total antioxidant capacity), and oxidative damage products (advanced oxidation protein products, advanced glycation end products (AGE), 8-isoprostanes, 8-hydroxy-2’-deoxyguanosine and total oxidant status) were estimated in non-stimulated and stimulated saliva, as well as in plasma and erythrocytes. We show that in dementia patients the concentration/activity of major salivary antioxidants changes, and the level of oxidative damage to DNA, proteins and lipids is increased compared to healthy controls. Non-stimulated and stimulated salivary secretions were significantly reduced in dementia patients. The deterioration in mini mental state examination (MMSE) score correlated with salivary AGE levels, which when considered with receiver operating characteristic (ROC) analysis, suggests their potential role in the non-invasive diagnosis of dementia. In conclusion, dementia is associated with disturbed salivary redox homeostasis and impaired secretory function of the salivary glands. Salivary AGE may be useful in the diagnosis of dementia.

27 October 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Karolina WilczyńskaKarolina Wilczyńska
Karolina Wilczyńska
Napoleon WaszkiewiczNapoleon Waszkiewicz
Napoleon Waszkiewicz
Introduction: Dementia is a group of disorders that causes dysfunctions in human cognitive and operating functions. Currently, it is not possible to conduct a fast, low-invasive dementia diagnostic process with the use of peripheral blood biomarkers, however, there is a great deal of research in progress covering this subject. Research on dementia biomarkers in serum validates anticipated health and economic benefits from early screening tests. Biomarkers are also essential for improving the process of developing new drugs. Methods: The result analysis, of current studies on selected biomarker concentrations (Aβ40, Aβ42, t-tau, and YKL-40) and their combination in the serum of patients with dementia and mild cognitive disorders, involved a search for papers available in Medline, PubMed, and Web of Science databases published from 2000 to 2020. Results: The results of conducted cross-sectional studies comparing Aβ40, Aβ42, and Aβ42/Aβ40 among people with cognitive disorders and a control group are incoherent. Most of the analyzed papers showed an increase in t-tau concentration in diagnosed Alzheimer’s disease (AD) patients’ serum, whereas results of mild cognitive impairment (MCI) groups did not differ from the control groups. In several papers on the concentration of YKL-40 and t-tau/Aβ42 ratio, the results were promising. To date, several studies have only covered the field of biomarker concentrations in dementia disorders other than AD. Conclusions: Insufficient amyloid marker test repeatability may result either from imperfection of the used laboratorial techniques or inadequate selection of control groups with their comorbidities. On the basis of current knowledge, t-tau, t-tau/Aβ42, and YKL-40 seem to be promising candidates as biomarkers of cognitive disorders in serum. YKL-40 seems to be a more useful biomarker in early MCI diagnostics, whereas t-tau can be used as a marker of progress of prodromal states in mild AD. Due to the insignificant number of studies conducted to date among patients with dementia disorders other than AD, it is not possible to make a sound assessment of their usefulness in dementia differential diagnostics.

13 September 2021 in Frontiers in Psychiatry
Verified
Journal Article
Open access
Karolina WilczyńskaKarolina Wilczyńska
Karolina Wilczyńska
MMMateusz Maciejczyk
Mateusz Maciejczyk
AZAnna Zalewska
Anna Zalewska
NWNapoleon Waszkiewicz
Napoleon Waszkiewicz
Introduction: The diagnosis and treatment of dementia is one of the greatest challenges in contemporary health care. The widespread use of dementia biomarkers would improve the quality of life of patients and reduce the economic costs of the disease. The aim of the study was to evaluate the usefulness of proteins related to the Alzheimer's disease pathogenesis—amyloid beta isoform (Aβ) and total tau protein (t-tau), as well as the quite recently discovered marker YKL-40 in the most common types of dementia.Methods: 60 dementia (AD—Alzheimer's disease, VaD—vascular dementia, MxD—mixed dementia) and 20 cognitively normal subjects over 60 years old were examined. Subjects with dementia of etiology different than AD or VaD and with neoplastic or chronic inflammatory diseases were excluded. Concentrations of Aβ40, Aβ42, t-tau, and YKL-40 were measured in serum using ELISA kits on admission and after 4 weeks of inpatient treatment. ANOVA and Tukey's test or Dunn's test were used to perform comparison tests between groups. Correlations were measured using Pearson's coefficient. Biomarker diagnostic utility was assessed with ROC analysis.Results: YKL-40 differentiates between cognitively normal and mild dementia patients with 85% sensitivity and specificity and t-tau with 72% sensitivity and 70% specificity. YKL-40 and t-tau concentrations correlate with each other and with the severity of clinically observed cognitive decline.Conclusions: YKL-40 is a sensitive and specific biomarker of early dementia and, to a lesser extent, of dementia progression, however, many comorbidities may influence its levels. In such conditions, less specific but still reliable t-tau may serve as an alternative marker. Obtained results did not confirm the diagnostic utility of amyloid biomarkers.

30 April 2020 in Psychiatria Polska
Verified
Journal Article
Open access
EREmil Rozenek
Emil Rozenek
WOWiktor Orlof
Wiktor Orlof
ZNZuzanna Nowicka
Zuzanna Nowicka
Karolina WilczyńskaKarolina Wilczyńska
Karolina Wilczyńska
Napoleon WaszkiewiczNapoleon Waszkiewicz
Napoleon Waszkiewicz
Niemożność mówienia w pewnych sytuacjach − tak najkrócej można scharakteryzować mutyzm wybiórczy (ang. Selective mutism, SM), który według najnowszych klasyfikacji (DSM-V, ICD-11) należy do spektrum zaburzeń lękowych. Pojawienie się mutyzmu wybiórczego w okresie wczesnodziecięcym może zaburzać dalszy rozwój, a także niekorzystnie wpływać na osiągnięcia edukacyjne. Zarówno psychiatrzy, jak i lekarze innych specjalizacji, logopedzi, pielęgniarki i nauczyciele powinni posiadać odpowiednią wiedzę na temat tego zaburzenia, ponieważ wcześnie podjęte leczenie wiąże się z lepszym rokowaniem. Celem niniejszego przeglądu literatury jest przybliżenie współczesnego spojrzenia na stosunkowo rzadki zespół psychopatologiczny jakim jest mutyzm wybiórczy. W świetle najnowszych badań dotyczących etiologii SM sam objaw mutyzmu wydaje się być jedynie wykładnikiem kryjącej się pod nim heterogennej grupy zaburzeń. Opierając się na psychopatologii rozwoju można wnioskować, że wzajemne powiązania między piętrzącymi się nieprawidłowościami sprzyjają ujawnieniu się SM w przełomowym okresie życia. Złożoność etiologiczna sugeruje multimodalne podejście do pacjenta w procesie diagnostyczno-terapeutycznym, co jest postulowane przez wielu autorów.

15 December 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Napoleon WaszkiewiczNapoleon Waszkiewicz
Napoleon Waszkiewicz
Katarzyna PawłowiczKatarzyna Pawłowicz
Katarzyna Pawłowicz
NONatalia Okuniewska
Natalia Okuniewska
MKMikołaj Kwiatkowski
Mikołaj Kwiatkowski
DDaniel Zalewski
Daniel Zalewski
Anna ZalewskaAnna Zalewska
Anna Zalewska
Serum carbohydrate-deficient transferrin (CDT), an 80 kDa glycoprotein, is one of the most commonly employed biomarkers to detect alcohol dependence. Some salivary glycoproteins such as α-amylase, clusterin, haptoglobin, light/heavy-chain immunoglobulin, and transferrin, which alter glycosylation in alcohol-dependent persons, have been suggested to be potential alcohol markers. However, their identification is based on indirect analysis of lectin glycosidic bonds and molecular weight. We investigated the CDT content in the saliva of alcohol- and nicotine-dependent men. The CDT concentration (ng/mL, ng/mg protein) was determined by an Enzyme-Linked Immunosorbent Assay (ELISA) commercial kit in 55 men: 20 healthy social drinkers (C), 10 chronic cigarette smokers (S), 10 alcohol-dependent non-smokers (A), and 15 alcohol-dependent smokers (AS). Surprisingly, there were no differences in the concentrations of CDT between the studied groups. Salivary pH was the lowest in the AS and the highest in the A group. Therefore, salivary CDT cannot be used as an alcohol dependence marker as measured by ELISA. We suggest that direct identification of glycoproteins is necessary to search for potential salivary alcohol biomarkers. Molecules smaller than 40 kDa, which easily translocate from blood to the saliva, might be preferred as salivary alcohol markers.

17 May 2018
Verified
Journal Article
Closed access
ESEwa Stefańska
Ewa Stefańska
AWAgnieszka Wendołowicz
Agnieszka Wendołowicz
MLMagdalena Lech
Magdalena Lech
Karolina WilczyńskaKarolina Wilczyńska
Karolina Wilczyńska
BKBeata Konarzewska
Beata Konarzewska
LOLucyna Ostrowska
Lucyna Ostrowska